MDM2 and cancer: USP7 is emerging as a drug target for cancer therapeutics because of its ability to stabilize multiple oncoproteins such as PHF8, MDM2, and β‐catenin.[28] Given that USP7 deubiquitylates and stabilizes RPAP2, RPAP2 may emerge as a potential biomarker for USP7‐targeted therapies.